Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Plunges 6%; BSE HEALTHCARE Index Down 0.4%
Thu, 29 Aug 10:52

Panacea Biotech Plunges 6%; BSE HEALTHCARE Index Down 0.4%Image source: ThinkNeo/www.istockphoto.com

Panacea Biotech share price has plunged 6% and is presently trading at Rs 233.7.

Meanwhile, the BSE HEALTHCARE index is at 42,578.0 (down 0.4%).

Among the top losers in the BSE HEALTHCARE index today are ALEMBIC PHARMA (down 2.8%) and SUN PHARMA ADV. RES. (down 1.8%).

AJANTA PHARMA (up 2.9%) and ERIS LIFESCIENCES (up 2.5%) are among the top gainers today.

Over the last one year, Panacea Biotech has moved up from Rs 138.6 to Rs 233.7, registering a gain of Rs 95.1 (up 68.6%).

On the other hand, the BSE HEALTHCARE index has moved up from 27,859.6 to 42,578.0, registering a gain of 52.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were GRANULES INDIA (up 136.4%), Glenmark Pharma (up 122.3%) and SUVEN PHARMACEUTICALS (up 108.7%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 82,007.9 (up 0.3%).

The top gainers among the BSE Sensex today are Bajaj Finance (up 2.6%) and Bajaj Finserv (up 2.3%). The most traded stocks in the BSE Sensex are Tata Steel and HDFC Bank.

In the meantime, NSE Nifty is at 25,098.7 (up 0.2%). Bajaj Finance and Bajaj Finserv are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 64,996.6 to 82,007.9, registering a gain of 17,011.3 points (up 26.2%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -50.5.


Equitymaster requests your view! Post a comment on "Panacea Biotech Plunges 6%; BSE HEALTHCARE Index Down 0.4%". Click here!